Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD7986 + verapamil
- Development stage
- Unknown
- Lead developer
- Insmed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD7986 + verapamil is an investigational drug combination studied primarily for pharmacokinetic interactions in healthy volunteers. AZD7986 is a selective inhibitor of dipeptidyl peptidase 1 (DPP1), which regulates activation of neutrophil serine proteases and is being developed for neutrophil-driven inflammatory diseases such as COPD. Verapamil is a calcium channel blocker, widely used as an antihypertensive and antiarrhythmic agent. The combination has been used in phase 1 studies to investigate the pharmacokinetics and potential drug-drug interactions of AZD7986 when coadministered with verapamil[1][2].
- Other names
- AZD7986 + verapamil
02
Targets
CTSC (DPP1)
Beyond the preview
Go deeper on AZD7986 + verapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD7986 + verapamil.